Introduction
A common feature of all retroviruses is the use of a cellular tRNA as a primer for reverse transcription in which the viral RNA genome is replicated into DNA prior to integration in the host cell chromosome (Gilboa et al., 1979; Mak and Kleiman, 1997) . The initiation of reverse transcription occurs at a region in the viral genome designated as the primer binding site (PBS) (Gilboa et al., 1979; Varmus and Swanstrom, 1982) . The PBS is complementary to the 3Ј-terminal nucleotides of the cellular tRNA molecule used for initiation (Gilboa et al., 1979; Varmus and Swanstrom, 1982) . Retroviruses have evolved to use specific tRNAs in reverse transcription (Mak and Kleiman, 1997) . For example, all lentiviruses, including human immunodeficiency virus, select tRNA Lys, 3 for reverse transcription (Mak and Kleiman, 1997) . Even though HIV-1 exclusively uses tRNA Lys, 3 , the virus has the capacity to use a wide variety of tRNAs if the PBS is altered to be complementary to the 3Ј 18 nucleotides of the alternative (non-tRNA Lys,3 ) tRNA (Das, Klaver, and Berkhout, 1995; Kang, Wakefield, and Morrow, 1996; Li et al., 1994; Wakefield, Wolf, and Morrow, 1995) . After short-term replication in culture though, all of these viruses revert back to utilize tRNA Lys, 3 as a primer. Several viruses have been engineered to utilize alternative tRNA primers by introducing additional mutations in the U5 A-rich loop complementary to the anticodon region of the alternative tRNA Kang, Zhang, and Morrow, 1999; Wakefield, Kang, and Morrow, 1996; Zhang et al., 1996) . Even with these mutations, not all anticodon-PBS combinations resulted in the stable utilization of alternative tRNA primers . Thus, the features for selection of the tRNA primer and the maintenance of the PBS complementary to tRNA Lys, 3 have not been completely elucidated. One of the more difficult questions to address in the selection process has been the role that availability of the tRNA primer plays in the selection process, since it is difficult to manipulate levels of tRNAs in eukaryotic cells. To address this question we have constructed a complementation system for HIV-1 using a provirus in which the PBS has been altered to be complementary to yeast tRNA Phe (Yu and Morrow, 1999; Yu and Morrow, 2000; Yu and Morrow, 2001) . Previous studies from this laboratory have shown that the infectivity of this virus requires cotransfection of yeast tRNA
Phe that can be prepared by in vitro transcription of the tRNA cDNA. Using this system, we have begun to dissect the elements of the tRNA molecule that is required for HIV-1 infectivity. Our previous studies clearly show that certain elements within the tRNA, such as the D-loop, are not necessary for HIV-1 infectivity, whereas other elements in the TC-loop of the tRNA are essential (Yu and Morrow, 1999 , 2000 .
Our studies to date have used in vitro transcribed tRNA to complement the defective HIV-1 proviral genome. Although this system has proven useful for delineation of some of the features of the tRNA for essential for HIV-1 replication, it does not reflect elements of the biogenesis common for all tRNAs. Following transcription of the tRNA gene by RNA polymerase III, the pre-tRNA undergoes 5Ј and 3Ј processing. Additional posttranscriptional modifications include modified nucleotides and CCA addition (Wolin and Matera, 1999) . Recent studies have found that aminoacylation can occur in the nucleus and may promote rapid export of the tRNA to the cytoplasm (Arts and Le Grice, 1998; Lund and Dahlberg, 1998) . Following transport, the tRNA is "channeled" into protein synthesis (Gorlich and Kutay, 1999; Wolin and Matera, 1999) . It has been estimated that approximately 30 intracellular proteins interact with the tRNAs during synthesis and use in translation. The amount of free tRNA (i.e., nonaminoacylated) is vanishingly low in cells (Ho and Kan, 1987; Wolin and Matera, 1999 ).
In the current study, we have examined whether yeast tRNA Phe can be expressed from its natural promoter in eukaryotic cells and if the endogenously expressed tRNA Phe can complement the infectivity of a proviral genome with a PBS complementary to yeast tRNA Phe . We have utilized cotransfection to demonstrate that the yeast tRNA Phe expressed using its cognate promoter can effectively complement HIV-1 infectivity up to levels approaching that obtained for wild-type genomes with a PBS complementary to tRNA Lys, 3 . We have also constructed cell lines which express yeast tRNA Phe and have shown that the majority of the tRNA Phe is aminoacylated, indicating its competency for entry into the normal tRNA biogenesis pathways within mammalian cells. Our studies demonstrate a correlation between the quantity of endogenously expressed yeast tRNA Phe and the amount of infectious virus produced in these cells. The results of our studies are discussed with respect to the role that the interaction between PBS and tRNA plays in selection of the tRNA primer required for HIV-1 replication.
Results

Intracellular expression of yeast tRNA Phe
A yeast tRNA
Phe gene was constructed using PCR extension with oligonucleotides designed to include the A and B box intragenic pol III promoters, thymidine nucleotides at the 3Ј terminus necessary for pol III termination, and a 5Ј leader sequence (Fig. 1) . Following PCR, the product was cloned into a plasmid and the DNA insert was completely sequenced. We found that many of the tRNA clones were genetically unstable following propagation in Escherichia coli, which was overcome, for the most part, by growth at low temperatures (Kelly and Morrow, unpublished observations) . The majority of the mutations routinely observed were either point mutations or deletions within the A box, rendering the intragenic pol III promoter inactive. We were, however, able to obtain a complete yeast tRNA Phe expression cassette after screening of several clones. The yeast tRNA Phe gene was also subcloned into a vector which allows for amplification in cells expressing the SV40 T antigen and was identified as pCI-Phe; again, the complete tRNA gene was sequenced prior to use in the complementation assay.
To determine if we would express tRNA Phe in cells, we collected total RNA from 293T cells transfected with increasing amounts of pCI-Phe. An oligonucleotide probe specific yeast tRNA Phe was used; human tRNA Phe differs from yeast tRNA Phe at 17 positions (Nazarenko et al., 1992) , allowing for high specificity of oligo probes complimentary to yeast tRNA Phe . Increasing concentrations of transfected pCI-Phe resulted in a corresponding increase in levels of yeast tRNA Phe in 293T cells ( Fig. 2A) .
Yeast tRNA Phe expressed in mammalian cells is aminoacylated
One of the bench marks for functional tRNA in the cell is the capacity to undergo aminoacylation. This process requires appropriate 5Ј or 3Ј processing, CCA addition and interaction with the appropriate aminoacyl-tRNA synthetase (Wolin and Matera, 1999 ). In addition, recent studies have shown that aminoacylation can facilitate rapid transport from the nucleus to the cytoplasm (Lund and Dahlberg, 1998) . Previous studies have shown that yeast tRNA Phe is an excellent substrate for mammalian phenylalanyl-tRNA synthetase and aminoacylation of yeast tRNA Phe readily occurs in vitro with the mammalian enzyme (Zakharova, Kotenko Iu, and Lavrik, 1990) . The capacity of yeast tRNA Phe to be processed and aminoacylated within mammalian cells has not been previously described. Since yeast tRNA Phe was being overexpressed after transfection of plasmid DNA, it was necessary to show that the foreign tRNA was being aminoacylated and complementation of an HIV-1 with a PBS complementary to yeast tRNA Phe did not result from selection of tRNA that was unable to enter the normal mammalian tRNA biogenesis pathways. To test for aminoacylation of the yeast tRNA Phe in mammalian cells, we analyzed the tRNA Phe from transfected cells by Northern blotting of total cellular RNA separated on a polyacrylamide gel buffered at pH 5 (Ho and Kan, 1987) . For comparison, we also analyzed endogenous levels of aminoacylation for tRNA Lys, 3 . We found that the vast majority of the tRNA Lys,3 isolated was aminoacylated (Fig. 2B) ; this result is consistent with what is known about the steady-state levels of tRNA in mammalian cells (Ho and Kan, 1987; Wolin and Matera, 1999) . Most importantly, we also found that the majority of the yeast tRNA Phe expressed from transfection of plasmids was aminoacylated. Collectively, these results show that the yeast tRNA Phe derived from transfection is aminoacylated and thus accesses the biosynthetic pathways and translational machinery of the cell.
Yeast tRNA Phe is incorporated into HIV-1 virions independent of the primer binding site
In previous studies, we have described an HIV-1 proviral genome in which the PBS has been altered to correspond to the 3Ј 18 terminal nucleotides of yeast tRNA Phe (Yu and Morrow, 1999 , 2000 . This defective proviral genome, designated psHIV-Phe, has an expression cassette consisting of the SV40 early promoter and a gene encoding xanthine-guanosine phosphoribosyl transferase (gpt) in place of a deleted env gene. Pseudoviruses were derived from cotransfection of psHIV-Phe and pLGRNL, which encodes the VSV-G protein.
As a first step in the characterization of our system, we analyzed HIV-1 virions for the incorporation of yeast tRNA Phe . To do this, we cotransfected psHIV-Phe or pHgWT (a plasmid containing the wild-type HIV-1 genome) along with increasing concentration of pCI-Phe. The amount of virus from the transfected cells was quantitated by the p24 antigen-capture ELISA. Equivalent amounts of p24 associated RNA were blotted onto a positively charged nylon membrane and probed for tRNA Lys, 3 or tRNA Phe . In general, the amounts of tRNA Lys,3 detected in virions for psHIV-Phe or psHGWT were not influenced by the coexpression of tRNA Phe (Fig. 3A ). This result is not entirely unexpected since in previous studies we have found HIV-1 that use an alternative tRNA primer (tRNA His ) had a similar profile of tRNA Lys1,2 /tRNA Lys,3 as did the wild-type virus (Zhang et al., 1996) . Thus, the incorporation of tRNA into HIV-1 virions is not dependent on complementarity with the PBS. In support of this, we found that the increased cytoplasmic expression of tRNA Phe resulted in an increase in tRNA Phe in virions derived from either psHIV-Phe or pHgWT (Fig. 3B ). The incorporation of tRNA Phe appeared to reach a plateau beginning with 1 g of cotransfect pCIPhe. Thus, the results of our studies demonstrate the capacity to increase the cytoplasmic amounts of tRNA Phe that results in the increased incorporation into HIV-1 virions. There is no inherent defect in yeast tRNA Phe for incorporation into virions and, similar to tRNA Lys,3 , tRNA Phe can be incorporated into virions regardless of complementarity with the PBS.
Complementation of psHIV-Phe infectivity
The most critical aspect of our system is to ascertain whether the expressed tRNA
Phe will complement infectivity of the defective virus. In our previous studies, we found that cotransfection of psHIV-Phe, pLGRNL, and in vitro-generated yeast tRNA Phe resulted in infectious virus as judged by the capacity to convert HeLa cells to resistance to mycophenolic acid. The colony forming unit (cfu) of infectious viruses generated following cotransfection was substantially above background levels seen in the absence of yeast tRNA Phe but significantly less than observed for viruses in which the PBS was complementary to tRNA Lys, 3 . The reason for the low complementation was not apparent. One possibility was that cotransfection of DNA (proviral plasmid and plasmid encoding VSV-G) and the synthetic tRNA Phe was low; this seemed unlikely because we were readily able to detect the transfected tRNA Phe at various times posttransfection. A more likely possibility is that the tRNA selection process is coordinated with proviral RNA synthesis and tRNA biogenesis. To address this issue, we developed a system whereby both the proviral genomes and tRNA cDNAs were cotransfected. To determine if plasmids encoding yeast tRNA Phe would rescue psHIV-Phe, we performed the cotransfection using a variety of plasmid concentrations (Fig. 4) . A dose response was established for the quantities of tRNA expressing plasmids by determining the titer of infectious virus that correlated with the numbers of drug-resistant colonies. In the case of the yeast tRNA Phe cloned into the TA vector, we found a linear increase in the number of colonies with the increasing amounts of transfected pTA-Phe, demonstrating that under these conditions the production of infectious virus was dependent on the amount of tRNA Phe expressing plasmid. We next analyzed the production of infectious virus using the plasmid pCI- Phe and tRNA Lys,3 from cells transfected with pTA-Phe. All lanes contain 2 g cytoplasmic RNA isolated under acidic conditions. The RNA loaded in lanes 2 and 4 were adjusted to pH 9.0 and incubated at 37°C for 1 h to serve as the deacylated controls. The migration of aminoacylated tRNA and deacylated control tRNA are denoted as AA and DA respectively. Lanes 1 and 2 were probed for yeast tRNA Phe and lanes 3 and 4 were probed for tRNA Lys, 3 . The exposure times for each blot were the same. Phosphorimage analysis of the AA versus DA in lanes 1 and 3 revealed a ratio of greater that 99 to 1 indicating that the vast majority of the yeast tRNA Phe and tRNA Lys,3 were isolated from the cells was aminoacylated.
Phe; in this case, the tRNA Phe gene is identical to that in pTA-Phe, but pCI-Phe contains an SV40 origin of replication to allow amplification in 293T cells. Using the same experimental conditions, we routinely found that greater number of drug-resistant colonies were obtained if pCI-Phe was substituted for pTA-Phe, presumably due to the fact that the 293T cells provide the necessary conditions for replication of the transfected plasmids containing the SV40 origin of replication. The amount of infectious virus reached a plateau of approximately 2700 colonies/ng p24 beginning at 1 g of cotransfected pCI-Phe. Using pCI-Phe with psHIV-Phe, we found that the number of drug-resistant colonies approached 50% of that seen for the transfection of pHgWT, where the PBS is complementary to tRNA Lys,3 and the production of infectious virus is dependent on endogenous levels of tRNA Lys, 3 . The level of complementation of psHIV-Phe with either plasmid (pCI-Phe or pTA-Phe) was greater than 40-fold above that previously reported for complementation with in vitro transcribed yeast tRNA Phe . Interestingly, the amounts of infectious virus plateaued at 1 g of pCI-Phe cotransfected with psHIV-Phe, whereas the amount of tRNA Phe produced increased following cotransfection with 2 g pCI-Phe and psHIV-Phe (Fig. 4) . Collectively, the results of these studies suggest that the HIV primer selection process can be saturated by increased amounts of expressed tRNA following transfection of cDNAs encoding the priming tRNA.
Generation of cell lines expressing yeast tRNA Phe and complementation of psHIV-Phe
The ability to transfect plasmids encoding yeast tRNA Phe for complementation of psHIV-Phe prompted us to determine whether we could generate cell lines for continuous expression of yeast tRNA Phe . Our strategy for generation of cell lines involved the linearization and transfection of pCIPhe encoding yeast tRNA Phe into 293 cells. Also present on the pCI-Phe vector is the neo gene that allowed for selection in the presence of G418; a control cell line was also developed by transfection of pCIneo that did not contain the tRNA Phe gene. Following selection with G418, individual cell clones were isolated and the cell numbers amplified. In general, we found that transfection of pCI-Phe gave relatively few colonies; this was not due to transfection since transfection of pCI gave rise to numerous colonies. Furthermore, many of the cell colonies obtained following transfection with pCI-Phe grew for a short time following cloning, but subsequently died. After numerous trials, we did isolate two stable cell lines following transfection with pCI-Phe. The cells grew similar to the control cells and were used to test for complementation of psHIV-Phe. Following cotransfection with psHIV-Phe and pLGRNL, the viruses produced were quantitated by p24 and used to reinfect HeLa H1 cells followed by selection with mycophenolic acid. Again, numbers of drug-resistant colonies reflect the titer of infectious virus. Both cell lines complemented psHIV-Phe at low levels, representing approximately 5% of that observed for complementation of the provirus (pHgWT) with PBS complementary to tRNA Lys, 3 (Fig. 5A) . This was not due to differences in transfection efficiencies between the different cell lines, since we used these same lines for transfections of the proviruses with a PBS complementary tRNA Lys,3 (pHgWT) and produced comparable levels of infectious virus obtained from transfection of 293 cells (data not shown).
To further investigate the reason for the low-level complementation in the cell lines, we compared the steadystate levels of yeast tRNA Phe with that of tRNA Lys, 3 . Total cellular RNA preparations from the cell lines were subjected to Northern blot analysis using oligonucleotide probes specific for yeast tRNA Phe or tRNA Lys, 3 . In this case, we found that we could readily detect tRNA Lys, 3 in the RNA preparations from both cell lines (Fig. 5B) . However, analyzing the same RNA samples for the presence of yeast tRNA Phe revealed that the tRNA Phe was present at a substantially lower amount than tRNA Lys, 3 . Quanitation of the blots by phosphorimaging revealed that the amount of yeast tRNA
Phe was approximately 0.1% of that for tRNA Lys, 3 . Further analysis revealed that the ratio of aminoacylated/ free for tRNA Phe in these cell lines was similar to that found for expression of tRNA Phe from plasmids (data not shown). Thus, using our selection scheme for cell lines producing yeast tRNA Phe , we had most likely selected for cells which produced yeast tRNA Phe but at a substantially lower level than that observed for tRNA Lys, 3 . Previous reports have indicated that overexpression of tRNAs can lead to cellular toxicity and may explain the inadvertent selection of lowproducing cell lines (Doerig et al., 1988; Hudziak, Schlessinger, and Ullrich, 1987; Laski et al., 1989) . What is most remarkable is that even with the low levels of yeast tRNA Phe , we could easily detect complementation of psHIV-Phe over background levels, indicating that high concentrations of primer need not be present within the cytoplasm for selection by HIV-1 for use in reverse transcription.
Discussion
In this report, we have used a novel complementation system that uses yeast tRNA Phe Lys, 3 . We found that the level of infectious virus obtained following transfection was proportional to the amount of yeast tRNA Phe produced within the cell; although at high concentrations of intracellular yeast tRNA Phe , we observed no increase in infectious virus, indicating that we had possibly saturated the selection mechanism. Finally, cells lines were isolated that expressed low levels of yeast tRNA Phe compared to tRNA Lys, 3 . Even with the low levels of tRNA Phe (relative to tRNA Lys,3 ), the cells lines complemented psHIV-Phe above background levels.
The complementation system described in this report is unique in that the production of infectious HIV-1 relies solely on the presence of yeast tRNA
Phe . In previous studies we found this virus was noninfectious, owing to the inability of mammalian tRNA Phe to be selected by the virus and used in reverse transcription Wakefield, Rhim, and Morrow, 1994) . To restore infectivity, yeast tRNA Phe generated from in vitro transcription was cotransfected with the proviral genome. The in vitro transcribed tRNA Phe was shown to complement at levels similar to that for tRNA Phe isolated from yeast, suggesting that Phe . The samples in lanes 1-5 were probed for yeast tRNA Phe , whereas lanes 6 -9 were probed for tRNA Lys, 3 . The order of the lanes are as follows: Lanes 1 and 8 contain 30 g total RNA from cell line 24A; lanes 2 and 9 contain 30 g total RNA from cell line 29B; Lanes 3 and 7 contain 30 g total RNA from normal 293 cells; lane 4 is blank; lanes 5 and 6 contain in vitro transcribed yeast tRNA Phe . The percentage of yeast tRNA Phe to tRNA Lys,3 was on the order of 0.1% as determined by phosphorimaging of the samples in lanes 1 and 2 compared to the same samples probed for tRNA Lys, 3 (lanes 8 and 9). The arrow denotes the migration of tRNA Phe and tRNA Lys, 3 . modified nucleotides in tRNA Phe are not essential for complementation (Yu and Morrow, 1999 , 2000 . Using this system, we were able to dissect the critical structural elements of the tRNA which are essential for HIV-1 to select and utilize as a primer for HIV-1 reverse transcription. However, this system relied on the introduction of in vitro transcribed tRNA Phe into the cytoplasm by transfection. It is unlikely that this tRNA would be recognized by the translational machinery of the cell (Gorlich and Kutay, 1999; Wolin and Matera, 1999) . In fact, previous studies have shown that tRNAs exogenously added to the cytoplasm were not aminoacylated, leading to the conclusion that the tRNA must be channeled into the protein synthesis machinery at some step(s) during tRNA biogenesis. Thus, it was possible that endogenously expressed tRNA Phe might not complement the defective HIV-1, since it might be incorporated into the translational machinery of the cell. To understand how the availability of a tRNA that is competent for entry into the translational machinery would affect the capacity to be selected by HIV-1 for reverse transcription, we refined our system so that the expression of the yeast tRNA Phe would occur from its cognate promoter following transfection in mammalian cells. If our system is to accurately reflect elements of the HIV-1 primer tRNA selection process, we would predict that the majority of the yeast tRNA Phe would be aminoacylated. Indeed, the vast majority of tRNA Lys, 3 and expressed tRNA Phe were aminoacylated. Consistent with this result, previous studies have shown that yeast tRNA Phe is a substrate for the mammalian phenylalanyl-tRNA synthetase in vitro and based on this study can also be efficiently aminoacylated in vivo (Zakharova, Kotenko Iu, and Lavrik, 1990) . Most importantly, we found that the ratio of tRNA Phe that was aminoacylated relative to free tRNA Phe was comparable to that of tRNA Lys, 3 . Thus, the tRNA Phe expression appears to reflect critical elements of the tRNA biogenesis.
Increasing concentrations of intracellular yeast tRNA Phe was associated with increased encapsidation into the virion. Overexpression of tRNA Lys,3 has also has been reported to be associated with increased incorporation into HIV-1 virions, although endogenous levels of tRNA Lys,3 precluded the determination of whether the excess tRNA Lys,3 expressed from transfection was actually used as a primer (Gabor et al., 2002) . Although an association with aminoacylation of tRNA and incorporation into virion has been found, an absolute relationship between the encapsidation of a tRNA and its use in reverse transcription has not been completely established . We found that tRNA Phe was encapsidated into wild-type virions that contain a PBS complementary to tRNA Lys, 3 virions. Previous studies from our laboratory have demonstrated that an HIV-1 that selectively uses tRNA His for reverse transcription during multiple rounds of replication maintains the same complement of tRNA Lys,3 /tRNA Lys1,2 as does the wild-type virus; however, there was not a selective enrichment of tRNA His (Zhang et al., 1996) . Consistent with these studies, alteration of the PBS to be complementary to tRNA Lys1,2 , which is enriched in the virion, does not result in HIV-1 using this tRNA for replication unless additional mutations are made in the U5 region (Kang, Zhang, and Morrow, 1999) . Collectively the results of these studies suggest that the encapsidation of tRNA might not be strictly coupled with the selection for use as a primer in reverse transcription. Additional studies using this complementation system where we can control the levels of the primer tRNA expression will help to clarify the relationship between tRNA encapsidation and use in replication.
The ability to shift the use of HIV-1 from tRNA Lys,3 to tRNA Phe by changing the PBS highlights the role that PBS: tRNA complementarity plays in the selection process. To date, the systems used to study HIV-1 primer selection have relied on the overexpression of wild-type or mutant tRNA Lys,3 (Gabor et al., 2002; Huang et al., 1994; Javanbakht et al., 2002) . However, this approach does not account for background levels of endogenous tRNA Lys, 3 and the effect of overexpression on the physiology of the cell. The complementation system described in this study relies on the expression of yeast tRNA Phe and, as we have shown, the increase in the production of infectious virus correlates with increases in cytoplasmic tRNA Phe expression with little to no background infectious virus. One element of the selection process that is now clear from our studies is that the virus must have either evolved mechanisms to identify the low levels of free tRNA in the cell for selection of the tRNA primer or is capable of capturing tRNA that is actively involved in protein synthesis. To select free tRNA, HIV-1 must have evolved a process to select the primer from a vanishingly small intracellular pool of tRNAs. In support of the alternative, that HIV-1 can select tRNAs that have been channeled into translation, we observed complementation from cell lines that produced yeast tRNA Phe at levels 0.1% of that of tRNA Lys, 3 . Even when expressed at these low levels, the majority of yeast tRNA Phe was aminoacylated, indicating that the tRNA was sequestered within the channeled tRNA cycle revolving around translation. Any model for the selection of the tRNA primer needs to take into account the fact that the majority of the tRNA in the cell, at any one time, is involved in protein synthesis (Negrutskii and Deutscher, 1991; Negrutskii, Stapulionis, and Deutscher, 1994; Sivaram and Deutscher, 1990; Stapulionis and Deutscher, 1995; Wolin and Matera, 1999) . The selection process may involve protein-tRNA complexes. Interestingly, several proteins that are responsible for channeling tRNAs through translation are also found within the HIV-1 virion, including EF1A and lysyl-tRNA synthetase (Cen et al., 2001; Cimarelli and Luban, 1999) . Future studies using the system described in this report will help to elucidate the role of protein-tRNA complexes in the tRNA selection process for HIV-1. Ultimately, these studies could lead to the development of new therapeutic strategies to disrupt this process and inhibit HIV replication.
Materials and methods
Tissue culture
The 293, 293T, and HeLa H1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf serum (FCS) and 1% antibiotic-antimycotic (Gibco/BRL, Gaithersburg, MD) (Zhang et al., 1998) . Cell lines producing yeast tRNA Phe were maintained in DMEM plus 15% fetal calf serum, 1% antibiotics, and 0.5 mg/ml G418 sulfate (Gibco/BRL, Gaithersburg, Maryland).
Construction of yeast tRNA Phe plasmids and cell lines
Two oligonucleotides (5Ј-TCTAGAATCGGATCCGTA-TACTCTTTCTTCAACAATTAGAGCTC GCGGATTTAG-CTCAGTTGGGAGAGCGCCAGACTGAAGATCTG-3Ј and 5Ј-GGATCCATGGTA CCCAAAAAATGCGAATTCT-GTGGATCGAACACAGGACCTCCAGATCTTCAGTCTG-3Ј) were used to construct the yeast tRNA Phe gene via PCR extension. The PCR product was then ligated into the pGEM-T Easy vector (Promega, Madison, WI). The resultant vector, pTAPhe, containing the yeast tRNA Phe expression cassette was digested with NaeI and NdeI generating a 543-bp fragment containing the transcriptional unit. The 543-bp fragment was cloned into pCI-neo (Promega) that had been digested with SmaI and NdeI; the plasmid was identified as pCI-Phe. All restriction enzymes were supplied by New England Biolabs (Beverly, MA). The correct sequence of the yeast tRNA Phe transcriptional unit contained in both pCI-Phe and pTA-Phe were verified by sequencing with the M13 Reverse Sequencing Primer (Promega). Cell lines expressing yeast tRNA Phe were constructed by CaPO 4 transfection of 293 cells with pCI-Phe that had been linearized by HpaI digestion; the CaPO 4 transfection kit was obtained from (Stratagene, San Diego, CA). After 24 h, the medium with CaPO 4 was replaced with DMEM plus 15% fetal calf serum, 1% antibiotics, and 0.5 mg/ml G418 sulfate (Gibco/BRL). Cells containing the pCI-Phe construct were selected with G418 for a duration of 2 weeks. Resistant cells were replated at low dilution and grown for 15 days in medium containing G418 when colonies from single cell clones were harvested and expanded to produce cell lines.
Transfection and selection of drug-resistant colonies
The procedure used for complementation of the defective HIV provirus, psHIV-Phe has been previously described (Yu and Morrow, 1999 , 2000 . Briefly, Mammalian Transfection Kit (Stratagene) was used for cotransfection of plasmid DNA (pLGRNL, psHIV-Phe or pHGWT, and pTAPhe or pCI-Phe) into 293T cells. For complementation in yeast tRNA
Phe cell lines; cell lines were cotransfected with pLGRNL and psHIVphe or pHgWT. At 48 h posttransfection, the supernatants were collected and filtered through a 0.45-m pore-size/low-protein binding filter (Pall Gelman Laboratory, Ann Arbor, MI). Virus production was monitored by p24 antigen levels using a commercial ELISA kit (Beckman Coulter, Miami, FL) . Different dilutions of viruses as measured by p24 produced by cotransfections were used to infect HeLa H1 cells. At 12 h after infection, the cells were washed with phosphate-buffered saline (PBS) and placed under selection with DMEM-XM media [DMEM containing 10% FCS, 1% antibiotics, 20 mM Hepes (pH 7.5), 250 g/ml xanthine, and 50 g/ml mycophenolic acid]. The media was replaced every 3 days until colonies of drug-resistant cells were formed (10 -14 days). Cell colonies were fixed with 5% TCA and stained with 2% Coomasie blue and number of drug-resistant colonies counted.
RNA isolation and analysis
Tri-Reagent (Sigma, St. Louis, MD) was used for the collection of total cellular RNA from yeast tRNA Phe cell lines and from 293T cells 48 h posttransfection with varied concentrations of pCI-Phe according to manufacturer's instructions. For RNA isolation from virions, 293T cells were cotransfected as previously described and resultant viruses were collected and filtered 48 h posttransfection. The numbers of virions were normalized by p24 and virion associated RNA was isolated via phenol/chloroform extraction. Prior to Northern blot analysis, residual plasmid DNA was removed from total RNA samples isolated from 293T cells transfected with varied concentrations of pCI-Phe via digestion with DNAfree (Ambion, Austin, TX) according to manufacturers instructions. For Northern blot analysis, oligonucleotide probes were designed to be complementary to yeast tRNA Phe and mammalian tRNA Lys,3 : tRNA Lys,3 probe oligo [5Ј-CGCCCGAACAGGGACTTGAACCCTGGACC-CTCAGATTAA AAGTCTGATGCTCTACCGACTGAGC-TATCC-3Ј] and tRNA Phe probe oligo [5Ј-TGCGAATTCTGT GGATCGAACACAGGACCTCCAGATCTTCAGTCTGGC-GCTCTCCCAACTGAGCTAAATCC-3Ј]. The probes were then 5Ј end-labeled with [␥-32 P]ATP using Ready-To-Go T4 polynucleotide kinase (Amersham Pharmacia Biotech, Piscataway, NJ). Free nucleotides were removed by centrifugation through ProbeQuant G-50 Micro Columns (Amersham Biosciences, Piscataway, NJ); equal amounts of (15 pmol) of probes were used for each blot (10 6 cpm/pmol). The NorthernMax-Gly kit (Ambion) was used according to manufacturer's instructions for Northern blotting and BrightStar-Plus (Ambion) was used as the positively charged nylon membrane. Blots were exposed on a phosphor screen and analyzed with a Phosphorimager. The percentage of yeast tRNA Phe relative to that of tRNA Lys, 3 in the same cell line was determined by volume analysis using ImageQuant v1.2 (Molecular Dynamics/Amersham Biosciences, Piscataway, NJ).
Assessment of tRNA aminoacylation status
To analyze the aminoacylation status of tRNAs, cytoplasmic RNA was isolated as previously described from Hela H1 cells 48 h posttransfection with pTA-Phe or from cell lines producing yeast tRNA Phe (Ho and Kan, 1987) . The cytoplasmic RNA was separated on an 8% polyacrylamide/8 M urea gel buffered with 0.1 M sodium acetate (pH 5) run at 400 V overnight at 4°C. The gel was soaked in 50 mM sodium acetate (pH 4.0) for 30 min and then transferred to BrightStar-Plus (Ambion) positively charged nylon membrane by downward transfer with 50 mM sodium acetate (pH 4.0) as a transfer buffer. The Northern blot and oligonucleotide probing was carried out as for total tRNA. For free tRNA (nonaminoacylated) controls, an aliquot of the tRNA was deacylated by incubation in 0.1 M Tris (pH 9.0) for 1 h at 37°C (Ho and Kan, 1987) .
